-
公开(公告)号：US20150273082A1
公开(公告)日：2015-10-01
申请号：US14680836
申请日：2015-04-07
Inventor： Amit Nathwani , Natalie Ward , Adrian Thrasher , Edward Tuddenham , John Mcvey , John Gray , Andrew Davidoff
IPC: A61K48/00 , A61K38/37 , C07K14/755 , C12N15/86 , C12N7/00
CPC classification number: A61K48/0058 , A61K38/00 , A61K38/37 , C07K14/755 , C12N7/00 , C12N15/86 , C12N2710/10041 , C12N2710/14143 , C12N2750/14143 , C12N2800/22 , C12N2830/008
Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocyte biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
Abstract translation: 人类血液凝固因子8（VIII）和启动子的优化编码序列可用于载体，例如rAAV，用于引入因子VIII和/或其它凝血因子和转基因。 这些因子和转基因的实例是α-1-抗胰蛋白酶，以及参与凝血级联，肝细胞生物学，溶酶体储存，尿素循环障碍和脂质储存疾病的那些因子和转基因。 由载体和序列转化的细胞产生的细胞，载体，蛋白质和糖蛋白可用于治疗。
-
公开(公告)号：US20220195013A1
公开(公告)日：2022-06-23
申请号：US17693785
申请日：2022-03-14
Applicant: THROMBOSIS RESEARCH INSTITUTE
Inventor： Xinjie Lu , Vijay Kakkar
IPC: C07K14/775 , A61K39/00 , A61K39/118 , C07K14/195 , C07K14/35 , C07K14/295 , C07K14/47 , C07K14/705
Abstract: The invention relates to multiple epitope constructs, immunogenic and vaccine compositions comprising recombinant molecules presenting inserted multiple and different epitopes from a variety of antigens. The antigenic determinants being associated with different pathways leading to atherosclerosis. In particular, the invention relates to such compositions for eliciting an immune response against antigens and pathogens involved in the development of atherosclerosis. The invention includes inter alia methods of treating and/or preventing the disease and recombinant protein products.
-
公开(公告)号：US11332515B2
公开(公告)日：2022-05-17
申请号：US15546858
申请日：2016-01-25
Applicant: THROMBOSIS RESEARCH INSTITUTE , Lord Kakkar
Inventor： Vijay Kakkar , Xinjie Lu
IPC: C07K14/775 , A61K39/00 , A61K39/118 , C07K14/195 , C07K14/35 , C07K14/295 , C07K14/47 , C07K14/705
Abstract: The invention relates to multiple epitope constructs, immunogenic and vaccine compositions comprising recombinant molecules presenting inserted multiple and different epitopes from a variety of antigens. The antigenic determinants being associated with different pathways leading to atherosclerosis. In particular, the invention relates to such compositions for eliciting an immune response against antigens and pathogens involved in the development of atherosclerosis the invention includes inter alia methods of treating and/or preventing the disease and recombinant protein products.
-
公开(公告)号：US12257319B2
公开(公告)日：2025-03-25
申请号：US16897900
申请日：2020-06-10
Inventor： Amit Nathwani , Natalie Ward , Adrian Thrasher , Edward Tuddenham , John McVey , John Gray , Andrew Davidoff
IPC: C07H21/04 , A61K31/70 , A61K38/37 , A61K48/00 , C07K14/755 , C12N7/00 , C12N15/63 , C12N15/86 , A01K67/00 , A61K38/00
Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocyte biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
-
Patent Agency Ranking
公开(公告)号：US20210000978A1
公开(公告)日：2021-01-07
申请号：US16897900
申请日：2020-06-10
Inventor： Amit Nathwani , Natalie Ward , Adrian Thrasher , Edward Tuddenham , John McVey , John Gray , Andrew Davidoff
IPC: A61K48/00 , C07K14/755 , C12N15/86 , A61K38/37 , C12N7/00
Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocyte biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
-
公开(公告)号：US10709796B2
公开(公告)日：2020-07-14
申请号：US15651698
申请日：2017-07-17
Inventor： Amit Nathwani , Natalie Ward , Adrian Thrasher , Edward Tuddenham , John McVey , John Gray , Andrew Davidoff
IPC: C07H21/04 , C12N15/00 , C12N15/63 , A61K48/00 , C07K14/755 , C12N15/86 , A61K38/37 , C12N7/00 , A01K67/00 , A61K38/00
Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes arc alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
-
公开(公告)号：US20180273608A1
公开(公告)日：2018-09-27
申请号：US15546858
申请日：2016-01-25
Applicant: THROMBOSIS RESEARCH INSTITUTE
Inventor： Vijay Kakkar , Xinjie Lu
IPC: C07K14/775 , C07K14/47 , C07K14/295 , C07K14/705 , A61K39/00 , A61K39/118
CPC classification number: C07K14/775 , A61K39/0005 , A61K39/0008 , A61K39/0012 , A61K39/118 , A61K2039/58 , A61K2039/6081 , A61K2039/64 , C07K14/195 , C07K14/295 , C07K14/35 , C07K14/47 , C07K14/70596
Abstract: The invention relates to multiple epitope constructs, immunogenic and vaccine compositions comprising recombinant molecules presenting inserted multiple and different epitopes from a variety of antigens. The antigenic determinants being associated with different pathways leading to atherosclerosis. In particular, the invention relates to such compositions for eliciting an immune response against antigens and pathogens involved in the development of atherosclerosis the invention includes inter alia methods of treating and/or preventing the disease and recombinant protein products
-
公开(公告)号：US20180008726A1
公开(公告)日：2018-01-11
申请号：US15651698
申请日：2017-07-17
Inventor： Amit Nathwani , Natalie Ward , Adrian Thrasher , Edward Tuddenham , John McVey , John Gray , Andrew Davidoff
Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes arc alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
-
公开(公告)号：US09764045B2
公开(公告)日：2017-09-19
申请号：US14680836
申请日：2015-04-07
Inventor： Amit Nathwani , Natalie Ward , Adrian Thrasher , Edward Tuddenham , John Mcvey , John Gray , Andrew Davidoff
IPC: C07H21/04 , C12N15/63 , A61K48/00 , C07K14/755 , C12N15/86 , A61K38/37 , C12N7/00 , A01K67/00 , A61K38/00
CPC classification number: A61K48/0058 , A61K38/00 , A61K38/37 , C07K14/755 , C12N7/00 , C12N15/86 , C12N2710/10041 , C12N2710/14143 , C12N2750/14143 , C12N2800/22 , C12N2830/008
Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.015 seconds)
